Numab Therapeutics, a Swiss clinical-stage biotechnology company, has announced a definitive agreement with Johnson & Johnson to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics (YJT) for $1.25 billion in cash. YJT includes the rights to NM26, a promising bi-specific antibody for the treatment of atopic dermatitis, which is poised to enter Phase 2 clinical development. Discovered through Numab’s MATCH technology platform, NM26 specifically targets IL-4R and IL-31 to address key aspects of atopic dermatitis pathology. Numab’s CEO, David Urech, emphasized the strategic importance of this transaction for accelerating the development of NM26 and vindicating Numab’s discovery platform. The acquisition is anticipated to close in the second half of 2024 following customary regulatory approvals. Morgan Stanley and Centerview Partners, along with legal advisor Baker McKenzie, facilitated the transaction on behalf of Numab.

Biotechnology, Pharmaceuticals, Healthcare,Switzerland, United States